Overview

Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis

Status:
Completed
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
The trial will be conducted as a prospective, randomized, multinational, multicenter, double-blind study in 4 parallel groups of patients. Approximately 900 patients with acute, uncomplicated rhinosinusitis will be randomized.
Phase:
Phase 3
Details
Lead Sponsor:
Sandoz
Treatments:
Acetylcysteine
N-monoacetylcystine